Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio that is above its average at 16.59x. The stock has a 36-month beta value of 2.17. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTGX is 55.65M, and at present, short sellers hold a 6.33% of that float. On October 11, 2024, the average trading volume of PTGX was 680.60K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PTGX) stock’s latest price update
Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has dropped by -1.34 in relation to previous closing price of 44.18. Nevertheless, the company has seen a loss of -1.69% in its stock price over the last five trading days. benzinga.com reported 2024-09-10 that Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.
PTGX’s Market Performance
Protagonist Therapeutics Inc (PTGX) has experienced a -1.69% fall in stock performance for the past week, with a -2.68% drop in the past month, and a 20.68% rise in the past quarter. The volatility ratio for the week is 2.73%, and the volatility levels for the past 30 days are at 3.58% for PTGX. The simple moving average for the past 20 days is -3.47% for PTGX’s stock, with a 33.37% simple moving average for the past 200 days.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with TD Cowen repeating the rating for PTGX by listing it as a “Buy.” The predicted price for PTGX in the upcoming period, according to TD Cowen is $65 based on the research report published on September 24, 2024 of the current year 2024.
Truist, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $60. The rating they have provided for PTGX stocks is “Buy” according to the report published on September 09th, 2024.
CapitalOne gave a rating of “Overweight” to PTGX, setting the target price at $32 in the report published on October 30th of the previous year.
PTGX Trading at 2.24% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.19% of loss for the given period.
Volatility was left at 3.58%, however, over the last 30 days, the volatility rate increased by 2.73%, as shares sank -4.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.43% upper at present.
During the last 5 trading sessions, PTGX fell by -1.69%, which changed the moving average for the period of 200-days by +96.00% in comparison to the 20-day moving average, which settled at $45.15. In addition, Protagonist Therapeutics Inc saw 90.10% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Ali Asif, who sale 14,203 shares at the price of $44.49 back on Sep 11 ’24. After this action, Ali Asif now owns 34,960 shares of Protagonist Therapeutics Inc, valued at $631,872 using the latest closing price.
Waddill William D., the Director of Protagonist Therapeutics Inc, sale 8,000 shares at $45.00 during a trade that took place back on Sep 10 ’24, which means that Waddill William D. is holding 12,000 shares at $360,000 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.48 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.53. The total capital return value is set at 0.27. Equity return is now at value 40.69, with 36.35 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 17.0. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 66.31.
Currently, EBITDA for the company is -90.34 million with net debt to EBITDA at -2.23. When we switch over and look at the enterprise to sales, we see a ratio of 6.97. The receivables turnover for the company is 232.93for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.73.
Conclusion
To sum up, Protagonist Therapeutics Inc (PTGX) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
